NIH Funds Translational Research Centers to Accelerate AD Drug Discovery
$73 million to transform big data into open-access targets and drugs for testing in clinical trials.
69 RESULTS
Sort By:
$73 million to transform big data into open-access targets and drugs for testing in clinical trials.
Negative findings for AVP-786 belie positive findings from a separate Phase 3 trial announced earlier this year.
The protein helps internalize neuronal interleukin receptors. It also promotes microglial phagocytosis. Does its absence worsen neuroinflammation and Aβ burden?
Using chemical cross-linkers to map contacts among amino acids, structural biologists predict that soluble tau is, in fact, a compact globule containing β-sheets poised to snap into a pathological formation.
New genes linked to early and late-onset AD offer up mechanistic insight, potential targets for treatment.
The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.
Different polymorphisms in MS4A genes up- or downregulate levels of TREM2, modulating levels of the shed ectodomain in the cerebrospinal fluid and AD risk.
In patient-derived neurons, tau mutations scupper lysosomes and SORLA shunts APP through different types of endosomes.
Changes in the composition of the cerebrospinal fluid and synapses may reveal novel insights into AD pathology.